

%20Banners%20(2).png)
Access to this event is by invitation only.
We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.
Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.
As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.
Hosts & Speakers

Agenda
Wednesday, December 10, 2025
12:00 - 1:30 PM ET I 9:00 AM - 10:30 PT
10 minutes
10 minutes
5 minutes
20 minutes
20 minutes
Welcome, with a preview of our 2025 Impact Report
Indu Navar, Founder & CEO, EverythingALS
James Berry, Chief of the Division of ALS and MND, MGB, Harvard Medical
Opening Keynote: Her Story, Person living with ALS
.Ivonne Vaughn will share her journey of daily living with ALS
New Consortium member introduction
A discussion of why and what they bring to the consortia; what they would like to accomplish
Transforming ALS Trial Recruitment: Removing Barriers to screening and enrollment with Generative AI - SAVA AI
Co-present with Dr. Jinsy Andrews on how Sava, the GenAI can transform trial navigation, empower patients with clearer guidance, and deliver more accurate, personalized trial matching
Advancing Clinical Endpoints: Speech-Listener's Effort, Gait/Balance
Discus New Endpoint Developments, Analytics Enhancements, and Digital Biomarker Progress
Closed session
END OPEN SESSION
CONSORTIA MEMBERS' Only
1:00-1:30 PM ET



































